| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S1542-3565(04)00060-6 |
| P698 | PubMed publication ID | 15067625 |
| P50 | author | Stephan R. Targan | Q106967049 |
| P2093 | author name string | Konstantinos A Papadakis | |
| Eric A Vasiliauskas | |||
| William S Mow | |||
| Howard E Pitchon | |||
| Maria T Abreu-Martin | |||
| P2860 | cites work | A simple classification of Crohn's disease: Report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998 | Q22252901 |
| Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent | Q28191546 | ||
| TNF-alpha, IL1-beta, and immunoglobulin (GM and KM) gene polymorphisms in sarcoidosis | Q28201837 | ||
| Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial | Q28202504 | ||
| Pentoxifylline treatment of mice with chronic pulmonary tuberculosis accelerates the development of destructive pathology | Q28361050 | ||
| Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice | Q29622922 | ||
| Infliximab for the treatment of fistulas in patients with Crohn's disease | Q33860666 | ||
| Role of cytokines in the pathogenesis of inflammatory bowel disease | Q33896046 | ||
| Immunological basis for reactivation of tuberculosis in mice | Q34007356 | ||
| Tumor necrosis factor: biology and therapeutic inhibitors | Q34065153 | ||
| IL-10-producing T cells suppress immune responses in anergic tuberculosis patients | Q35159232 | ||
| Intracellular cytokine repertoire in different T cell subsets from patients with sarcoidosis | Q35534544 | ||
| Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden. | Q35551908 | ||
| Critical roles for interleukin 1 and tumor necrosis factor alpha in antibody-induced arthritis | Q36371110 | ||
| Efficacy and safety of repeated infliximab infusions for Crohn's disease: 1-year clinical experience | Q43622497 | ||
| The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection | Q43831403 | ||
| Classification of inflammatory bowel disease | Q44185737 | ||
| Oral terbutaline differentially affects cytokine (IL-10, IL-12, TNF, IFNg) release in multiple sclerosis patients and controls | Q44205715 | ||
| Reliability of tuberculin purified derivative skin testing and delayed-type hypersensitivity skin test anergy in HIV-infected homosexual men, at risk of tuberculosis | Q45214640 | ||
| Skin test anergy in advanced heart failure secondary to either ischemic or idiopathic dilated cardiomyopathy. | Q46039172 | ||
| Granuloma formation is required to contain bacillus growth and delay mortality in mice chronically infected with Mycobacterium tuberculosis. | Q52537202 | ||
| A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. | Q53964227 | ||
| Invasive Pulmonary Aspergillosis Associated with Infliximab Therapy | Q57780453 | ||
| The differential diagnosis of idiopathic inflammatory disease by colorectal biopsy | Q69226610 | ||
| Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients | Q73697827 | ||
| Tuberculosis--the global view | Q74053563 | ||
| Changes in the transmission of tuberculosis in New York City from 1990 to 1999 | Q74053576 | ||
| Tuberculosis infection and anergy in hemodialysis patients | Q74557423 | ||
| Reactivation of histoplasmosis after treatment with infliximab | Q77549337 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | patient | Q181600 |
| inflammation | Q101991 | ||
| inflammatory bowel diseases | Q917447 | ||
| P304 | page(s) | 309-313 | |
| P577 | publication date | 2004-04-01 | |
| P1433 | published in | Clinical Gastroenterology and Hepatology | Q5133759 |
| P1476 | title | High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy | |
| P478 | volume | 2 |
| Q37814549 | A decade of infliximab: The Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease. |
| Q49821178 | Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1: risk assessment |
| Q50098797 | Asian Organization for Crohn's and Colitis and Asian Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1: Risk assessment |
| Q35537181 | BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment |
| Q37960183 | Biological therapies for inflammatory bowel disease: controversies and future options |
| Q35579308 | Biologics in paediatric Crohn's disease |
| Q90339285 | British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults |
| Q40680333 | Comparison of in vitro-specific blood tests with tuberculin skin test for diagnosis of latent tuberculosis before anti-TNF therapy |
| Q90393140 | Concordance between tuberculin skin test and interferon-gamma release assay for latent tuberculosis screening in inflammatory bowel disease |
| Q53648894 | Corticosteroids and immunosuppressive therapy influence the result of QuantiFERON TB Gold testing in inflammatory bowel disease patients. |
| Q37467519 | Cost-effectiveness of QuantiFERON testing before initiation of biological therapy in inflammatory bowel disease. |
| Q33725615 | Defining quality indicators for best-practice management of inflammatory bowel disease in Canada |
| Q33882852 | Diagnosis and Treatment of Latent Tuberculosis Infection due to Initiation of Anti-TNF Therapy |
| Q27005716 | Diagnosis and Treatment of Latent Tuberculosis Infection in Patients with Inflammatory Bowel Diseases due to Initiation of Anti-Tumor Necrosis Factor Therapy |
| Q48786898 | Diagnosis and management of inflammatory bowel disease in children. |
| Q40282145 | Early Tuberculin Skin Test for the Diagnosis of Latent Tuberculosis Infection in Patients with Inflammatory Bowel Disease. |
| Q41686103 | Evaluation of the usefulness of interferon-gamma release assays and the tuberculin skin test for the detection of latent Mycobacterium tuberculosis infections in Korean rheumatic patients who are candidates for biologic agents. |
| Q54422584 | Fecal polymerase chain reaction for Mycobacterium tuberculosis IS6110 to distinguish Crohn's disease from intestinal tuberculosis. |
| Q37547079 | General health maintenance in IBD. |
| Q37492482 | Health supervision in the management of children and adolescents with IBD: NASPGHAN recommendations |
| Q43450427 | Humoral and cellular monitoring to predict the development of infection in Crohn's disease patients beginning treatment with infliximab |
| Q47258498 | Indeterminate QuantiFERON-TB Gold Increases Likelihood of Inflammatory Bowel Disease Treatment Delay and Hospitalization. |
| Q38138343 | Infectious and malignant complications of TNF inhibitor therapy in IBD. |
| Q37012073 | Infliximab therapy for pediatric Crohn's disease |
| Q36903742 | Infliximab therapy in children and adolescents with inflammatory bowel disease |
| Q47616807 | Infliximab: Use in Inflammatory Bowel Disease |
| Q41060037 | Interferon γ-release assays for detecting latent tuberculosis infection in patients scheduled for anti-TNFα therapy |
| Q35199257 | Latent tuberculosis screening tests and active tuberculosis infection rates in Turkish inflammatory bowel disease patients under anti-tumor necrosis factor therapy |
| Q37630746 | Managing the risks of IBD therapy |
| Q30450875 | Medical management of Crohn's disease: current therapy and recent advances |
| Q36171733 | Methods to avoid infections in patients with inflammatory bowel disease |
| Q81574484 | Minimizing infliximab toxicity in the treatment of inflammatory bowel disease |
| Q83333104 | Mycobacterium avium subspecies paratuberculosis: a human pathogen causing most cases of Crohn's disease |
| Q45095583 | Negative effect of immunosuppressive therapy in the performance of the QuantiFERON gold in-tube test in patients with immune-mediated inflammatory diseases |
| Q26801119 | Optimal Endpoint of Therapy in IBD: An Update on Factors Determining a Successful Drug Withdrawal |
| Q37687869 | Optimizing the safety of biologic therapy for IBD. |
| Q40159900 | Performance of QuantiFERON(®)-TB Gold In-Tube assay in children receiving disease modifying anti-rheumatic drugs |
| Q37980410 | Performance of interferon-gamma release assays in patients with inflammatory bowel disease: a systematic review and meta-analysis. |
| Q43551029 | Prescribing patterns and awareness of adverse effects of infliximab: a health survey of gastroenterologists |
| Q38567716 | Pretravel preparation and travel-related morbidity in patients with inflammatory bowel disease |
| Q35597763 | Preventing TB in patients with Crohn's disease needing infliximab or other anti-TNF therapy |
| Q43663890 | QuantiFERON TB gold testing for tuberculosis screening in an inflammatory bowel disease cohort in the United States |
| Q40440524 | Rapid immunodiagnosis of tuberculosis in a woman receiving anti-TNF therapy |
| Q81972131 | Repeated tuberculin skin testing following therapy with TNF-alpha inhibitors |
| Q37114650 | Review and clinical perspectives for the use of infliximab in ulcerative colitis |
| Q50059459 | Risk factors for opportunistic infections in infliximab-treated patients: the importance of screening in prevention. |
| Q38306689 | Risk of tuberculosis in patients treated with anti-tumor necrosis factor therapy: a nationwide study in South Korea, a country with an intermediate tuberculosis burden |
| Q58924859 | Role of the T-cell interferon-gamma release assays in preventing reactivation of latent tuberculosis infection in immunosuppressed patients in treatment with anti-TNF agents |
| Q88653928 | Screening for latent tuberculosis infection in patients with inflammatory bowel disease: Can interferon-gamma release assays replace the tuberculin skin test? |
| Q40000660 | Screening for tuberculosis and hepatitis B prior to the initiation of anti-tumor necrosis therapy |
| Q35188622 | Significant risk and associated factors of active tuberculosis infection in Korean patients with inflammatory bowel disease using anti-TNF agents |
| Q53075558 | T-cell profiling and the immunodiagnosis of latent tuberculosis infection in patients with inflammatory bowel disease. |
| Q37918330 | The London position statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: safety |
| Q54259381 | The conundrum of indeterminate QuantiFERON-TB Gold results before anti-tumor necrosis factor initiation. |
| Q50957661 | The impact of immunosuppressive therapy on QuantiFERON and tuberculin skin test for screening of latent tuberculosis in patients with inflammatory bowel disease scheduled for anti-TNF therapy. |
| Q80539055 | The usefulness of PPD testing in inflammatory bowel disease patients before infliximab therapy |
| Q39044550 | Tuberculosis Screening and Reactivation Among a National Cohort of Patients with Inflammatory Bowel Disease Treated with Tumor Necrosis Factor Alpha Antagonists |
| Q36647175 | Tuberculosis in children: an update |
| Q40672157 | Tumour necrosis factor inhibitors and infection: What is there to know for infectious diseases physicians? |
| Q37769253 | Use of immunomodulators and biologic therapies in children with inflammatory bowel disease |
| Q37506064 | Use of infliximab in particular clinical settings: management based on current evidence |
| Q53248630 | Usefulness of two interferon-γ release assays for rheumatic disease. |
| Q83781503 | [Pulmonary tuberculosis testing and prevention of tuberculosis in patients taking anti-TNF medications] |
| Q84036425 | [Recommendations for tuberculosis screening before initiation of TNF-alpha-inhibitor treatment in rheumatic diseases] |
| Q81013607 | [TNF-alpha inhibitors in inflammatory bowel disease] |
Search more.